Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR pos RET C634W |
| Therapy | Motesanib Diphosphate |
| Indication/Tumor Type | medullary thyroid carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR pos RET C634W | medullary thyroid carcinoma | predicted - sensitive | Motesanib Diphosphate | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803). | 21422803 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21422803) | Anti-tumor activity of motesanib in a medullary thyroid cancer model. | Full reference... |